Objective: A number of studies have demonstrated that molecules called 'alarmins' or danger-associated molecular patterns (DAMPs), contribute to inflammatory processes in the OA joint. Metabolic reprogramming of immune cells, including macrophages, is emerging as a prominent player in determining immune cell phenotype and function. The aim of this study was to investigate if basic calcium phosphate (BCP) crystals which are OA-associated DAMPs, impact on macrophage phenotype and metabolism. Methods: Human monocyte derived macrophages were treated with BCP crystals and expression of M1 (CXCL9, CXCL10) and M2 (MRC1, CCL13)-associated markers was assessed by real-time PCR while surface maturation marker (CD40, CD80 & CD86) expression was assessed by flow cytometry. BCP induced metabolic changes were assessed by Seahorse analysis and glycolytic marker expression (hexokinase 2(HK2), Glut1 and HIF1a) was examined using real-time PCR and immunoblotting. Results: Treatment with BCP crystals upregulated mRNA levels of CXCL9 and CXCL10 while concomitantly downregulating expression of CCL13 and MRC1. Furthermore, BCP-treated macrophages enhanced surface expression of the maturation makers, CD40, CD80 and CD86. BCP-treated cells also exhibited a shift towards glycolysis as evidenced by an increased ECAR/OCR ratio and enhanced expression of the glycolytic markers, HK2, Glut1 and HIF1a. Finally, BCP-induced macrophage activation and alarmin expression was reduced in the presence of the glycolytic inhibitor, 2-DG. Conclusions: This study not only provides further insight into how OA-associated DAMPs impact on immune cell function, but also highlights metabolic reprogramming as a potential therapeutic target for calcium crystal-related arthropathies. Osteoarthritis and Cartilage xxx (xxxx) xxx Please cite this article as: Mahon OR et al., Osteoarthritis-associated basic calcium phosphate crystals alter immune cell metabolism and promote M1 macrophage polarization, Osteoarthritis and Cartilage, https://doi.
Introduction
Osteoarthritis (OA) is the most common form of chronic arthropathy and leading cause of disability worldwide. It affects 10% of males and 18% of females over the age of 45, a figure that is set to rise as life expectancy increases 1, 2 . In addition, the current obesity epidemic has resulted in an increased incidence of OA in younger individuals, many of whom will undergo multiple joint replacements due to the limited lifespan of artificial joints.
Extensive research has highlighted a complex interplay between chondrocytes, synovial fibroblasts and the innate immune network and while much progress has been made in elucidating the cellular and molecular events contributing to OA, the complex nature of the disease has hampered the development of a successful diseasemodifying drug. Current therapies are focused on providing symptomatic relief rather than halting or reversing disease progression, hence, there is a clear need to identify specific orchestrators that initiate and/or contribute to eventual joint destruction.
Immunometabolism is an emerging field of research that focuses on changes in intracellular metabolic pathways in immune cells and how these alterations impact on cell fate and function 3e5 . It is now recognised that a metabolic shift from oxidative phosphorylation to a highly metabolically active glycolytic state (designed to maintain energy homeostasis under conditions of low oxygen and acute stress) can lead to an accumulation of reactive oxygen species (ROS) and metabolic intermediates that promote the synthesis of degradative enzymes and inflammatory mediators 6 . Increased glycolytic rates and glucose consumption are associated with enhanced expression of the glucose transporter, GLUT1, as well as elevated lactate production 7 . Furthermore, activated immune cells exhibit Warburg metabolism and HIF-1a induction even under normoxic conditions 8, 9 . Recent studies have also demonstrated that macrophage activation and phenotype is intricately linked to cellular metabolic status. For example, lipopolysaccharide (LPS) activated M1 macrophages [M1(LPS)] exhibit an enhanced glycolytic profile characterised by increased expression of glucose transporters, glycolytic enzymes and rapid production of ATP 3, 10, 11 . While this metabolic switch is required to meet the energy demands of the cell during infection and provide biosynthetic components required to carry out effector functions, dysregulated immune-cell metabolism which results in sustained inflammatory responses, has been linked to a number of debilitating diseases and it has been strongly suggested that strategies to modulate metabolic reprogramming represents a novel approach to regulate disease pathology 12e15 . Furthermore, a number of metabolites have been shown to alter macrophage polarization and there is now a host of studies demonstrating how inhibitors of metabolism (e.g., glycolysis, fatty acid synthesis and fatty acid oxidation) can regulate immune responses providing potential new avenues to manipulate immune cell activation 15 .
Altered immunometabolism has been recognised as a component of a number of inflammatory and autoimmune conditions 13e17 and while it is well established that glycolysis is important for energy production in chondrocytes, there is now also evidence for increased glycolysis and deregulated cellular metabolism in OA 18e21 . Indeed, mitochondrial dysfunction is a hallmark of OA and previous studies have shown increased mitochondrial DNA damage in OA chondrocytes compared to healthy controls suggesting that cartilage degradation during OA and normal cartilage aging may be metabolically different processes 22 . Furthermore, lactate levels are elevated in OA and are frequently co-associated with crystal arthropathy comorbidities 23, 24 . Indeed, one notable link between mechanical and inflammatory mechanisms in OA pathogenesis is calcium crystal deposition. Basic calcium phosphate (BCP) crystals, comprised mainly of hydroxyapatite, are uniquely associated with OA and have been identified in 100% of cartilage and 50% of synovial fluid samples at the time of joint replacement where their concentration correlates with the severity of histological and radiographic OA 25 . Crystal deposition and articular calcification occurs as a result of dysregulated ossification processes and an imbalance between pro-mineralization and anti-mineralization factors. Direct injection of BCP-crystals into mouse knees results in synovial inflammation, cartilage destruction and chondrocyte apoptosis 26 . As a result, these crystals are now considered damage-associated molecular patterns (DAMPs) or 'alarmins' as they can activate fibroblasts, macrophages and chondrocytes through a variety of signaling pathways which, in turn, leads to the production of inflammatory and catabolic mediators 27e32 . While several pathological cellular mechanisms have been identified, studies examining the effects of BCP crystals in humans are lacking as are drugs that prevent crystal deposition, permit crystal dissolution or specifically target the pathogenic effects that result in clinical manifestations. In this study we demonstrate that BCP crystals polarize primary human macrophages towards an M1-like phenotype and upregulate the expression of glycolytic markers. This is accompanied by a bioenergetics switch in favour of glycolysis. Furthermore, we demonstrate that targeting glycolysis reduces BCP-induced macrophage polarization and alarmin expression, suggesting that calcium crystal deposition impacts on immune cell metabolic reprogramming and subsequent macrophage phenotype and function.
Methods
Reagents and assessment of endotoxin contamination in BCP preparations are described in supplementary methods.
Human blood monocyte-derived macrophage isolation
This study was approved by the research ethics committee of the School of Biochemistry and Immunology, Trinity College Dublin and was conducted in accordance with the Declaration of Helsinki. Leucocyte-enriched buffy coats from anonymous healthy donors were obtained with permission from the Irish Blood Transfusion Board (IBTS), St. James's Hospital, Dublin. Donors provided informed written consent to the IBTS for their blood to be used for research purposes. PBMC were isolated and differentiated into macrophages as described previously 33 . The purity of CD14 þ CD11b þ macrophages was assessed by flow cytometry and was routinely >95% (Fig. S1 ).
Cytokine measurements
Cells were pre-treated with PD98059 (20 mM), SB203580 (20 mM), for 45 min prior to stimulation with BCP crystals (50 mg/ ml) for 24 h. Supernatants were harvested and cytokine concentrations of TNFa, IL-6 and IL-8 were quantified by ELISA (eBioscience, San Diego, CA) according to manufacturer's protocol.
Real-time PCR
Macrophages were treated with BCP crystals (50 ug/ml) alone or in the presence of indicated inhibitors (PD98059 (20 mM), SB203580 (2 0mM), Latrunculin B (1 mM), Cytochalsin D (5 mM), Cytochalsin B (5 mM), Dynasore (80 mM) or 2-DG (25 mM). RNA was extracted using High-Pure RNA Isolation Kits (Roche), and assessed for concentration and purity using the NanoDrop 2000c UVeVis spectrophotometer. RNA was equalised and reverse transcribed using the Applied Biosystems High-Capacity cDNA reverse transcription kit. Real-time PCR carried out on triplicate cDNA samples using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, California). Reactions included iTaq Universal SYBR Green Supermix (Bio-rad Laboratories), cDNA, TaqMan fast universal PCR Master Mix and pre-designed TaqMan gene expression probes (Applied Biosystems) for CXCL9, CXCL10, MRC1, CCL13, S100A8 and the housekeeping gene, 18S ribosomal RNA. The 2ÀDDCT method was used to analyse relative gene expression. Oligonuceotide primer sequences for SYBR primers for HK2, Glut1, HIF1a, HIF2, GAPDH and HRPTL are provided in Supplementary  Table 1 .
Immunoblotting
Primary macrophages were stimulated BCP crystals (50 mg/ml) for 3, 6, or 24 h for the detection Hexokinase 2 (HK2), Glut1 or HIF1a protein. Cells were lysed by addition of RIPA buffer (Tris 50 mM; NaCl 150 mM; SDS 0.1%; sodium deoxycholate 0.5%; Triton X 100). Lysates were electrophoresed on SDS-PAGE gels (12% gel for Glut1, 10% gel for HK2 and 7.5% gel for HIF1a) and transferred to PVDF membranes (Millipore, Massachusetts) prior to detection with anti-HK2 or anti-Glut1 antibodies (Supplementary Table 2 ).
Flow cytometry
Primary human macrophages were plated at a concentration of 1 Â 10 6 cells/ml and stimulated with BCP crystals (50 mg/ml) for 24 h in the absence or presence of the glycolytic inhibitor 2-DG (25mM). Cells were collected, washed, Fcg blocked and stained extracellularly with amine-binding markers for dead cells (Fixable Viability Dye; eBioscience) for 10 min. Cells were washed in PBS and stained with fluorochrome-conjugated antibodies specific for CD14, CD11b, CD86, CD40 and CD80 (all eBiosciences) and fixed with 2% paraformaldehyde (PFA) washed and acquired. The model antigen DQ-Ova, which fluoresces upon processing by proteases inside the cell, was used to assess phagocytic capacity of the cells. Macrophages were cultured with complete RPMI containing DQ-Ovalbumin (500 ng/ml; Invitrogen) for 20 min at 37 C, followed by incubation for 10 min at 4 C. Cells were then washed in PBS and immediately acquired. Cells were acquired on a FACSCanto TM II (BD Biosciences) and analysis was performed with FlowJo v.10 so ware (Tree Star Inc.). Gating strategies utilised in all experiments are detailed in Supplementary Fig. 1 .
Seahorse analyser
Macrophages were cultured at 1 Â 10 6 cells/ml for 6 days prior to re-seeding at 2 Â 10 5 cells/well in a Seahorse 96-well microplate and allowed to rest for 5 h prior to BCP or LPS stimulation. The Seahorse cartridge plate was hydrated with XF calibrant fluid and incubated in a non-CO 2 incubator at 37 C for a minimum of 8 h prior to use. To determine the effect of BCP crystals, macrophages were incubated with BCP crystals (50 ug/ml) for 24 h, prior to analysis using a Seahorse XFe24 analyser. 30 min prior to placement into the XF/XFe analyser, cell culture medium was replaced with complete XF assay medium (Seahorse Biosciences; supplemented with 10mM glucose, 1mM sodium pyruvate, 2mM Lglutamine, and pH adjusted to 7.4) and incubated in a non-CO 2 incubator at 37 C. Blank wells (XF assay medium only) were prepared without cells for subtracting the background oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) during analysis. Oligomycin (1 mM; Cayman Chemicals), carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (1 mM; Santa Cruz biotechnology), rotenone (500 nM), and antimycin A (500 nM) and 2-deoxy-D-glucose (2-DG) (25 mM; all SigmaeAldrich) were prepared in XF assay medium and loaded into the appropriate injection ports on the cartridge plate and incubated for 10 min in a non-CO 2 incubator at 37 C. OCR and ECAR were measured over time with sequential injections of oligomycin, FCCP, rotenone and antimycin A and 2-DG. Analysis of results was performed using Wave software (Agilent Technologies). The rates of basal glycolysis, max glycolysis, glycolytic reserve etc. were calculated as detailed in the manufacturer's protocol and supplied in Supplementary  Table 3 .
Statistical analysis
Each experiment was performed in at least four healthy donors (defined by N) with 3e4 technical replicates run for each experiment, (defined by n) depending on the assay type. Paired one-way ANOVA or KruskaleWallis tests were used for the comparison of more than two groups for parametric and non-parametric analysis respectively, with the Tukey or Dunn's post-test (where applicable). A paired Student's t-test was used when there were only two groups for analysis and the data was normally distributed and a Two-tailed paired Wilcoxon Signed rank test was used for nonparametric data. All statistical analysis was performed on GraphPad Prism 7.00 (GraphPad Software). P value < 0.05 were deemed significant.
Results

BCP crystals promote M1 macrophage polarization
We and others have previously reported that BCP-crystals drive inflammatory mediator and alarmin production in macrophages, fibroblasts and chondrocytes 27, 29, 32 . In order to determine if BCP crystals impact on macrophage polarization, primary human macrophages were treated with previously published doses of BCP crystals (50 mg/ml) for . Treatment of macrophages with BCP-crystals did not induce secretion of the cytokines TNFa or IL-6 ( Fig. S2(A) ) which is in agreement with published results examining BCPinduced responses in macrophages 30 and together with results from the HEK-Blue™ hTLR4 assay system (Invivogen) ( Fig. S2(B) ) signifies a lack of endotoxin contamination in our BCP crystal preparation.
We have previously demonstrated that BCP crystals activate MAPKs downstream of Syk in a receptor independent manner 29, 30 . Pre-treatment of macrophages with either SB203580 or PD98059 to inhibit p38 and ERK, respectively, significantly inhibited BCPinduced IL-8, CXCL9 and CXCL10 expression [ Fig. 1 (F)e(H)], demonstrating that MAPK activation is also involved BCP-induced macrophage polarization. Of note, inhibition of MAPKs had no effect on MRC1 or CCL13 mRNA expression in BCP treated macrophages (Fig. S3 ). In addition to CXCL9/10 expression, we assessed surface expression of the M1-associated maturation markers, CD86, CD80, CD40 [ Fig. 1 (I) and (J)]. BCP crystals stimulation induced a significant increase in the expression of CD86 and CD40, and although not significant, a trend towards increased CD80 surface marker expression was also observed (p ¼ 0.0674). Finally, the phagocytic capacity of macrophages was assessed following BCP stimulation given that activated M1-like macrophages reduce their phagocytic capacity upon activation 34 . Cells were incubated with FITC-conjugated DQ-Ovalbumin (DQ-Ova) at 500 ng/ml post BCP stimulation and analysed for antigen uptake by flow cytometry. As expected, unstimulated macrophages exhibited high DQ-Ova uptake, however, this was significantly reduced upon stimulation of cells with BCP crystals [ Fig. 1(K) and (L)].
BCP crystals alter macrophage metabolism and promote glycolysis
A number of studies have demonstrated that activated macrophages exhibit an enhanced glycolytic profile characterised by increased expression of glucose transporters and glycolytic enzymes 35 . In order to determine whether BCP crystal-induced macrophage polarization coincided with a metabolic switch favoring glycolysis, macrophages were treated with BCP and established markers of glycolysis were assessed by real-time PCR and immunoblotting. BCP crystals significantly upregulated mRNA expression of the glucose transporter, GLUT 1 the glycolytic enzyme, hexokinase 2 (HK2) and the transcription factor, HIF1a. There was also a trend towards increased expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (p ¼ 0.0634) [ Fig. 2(A) ]. No difference in mRNA expression of HIF2a was observed (Fig. S4 ). Furthermore, protein levels of both HK2 and GLUT1 and were found to be highly expressed at 24 h post BCP crystal treatment, while increased expression of HIF1a was observed at 3, 6 and 24 h post stimulation [ Fig. 2(B) ]. Densitometric analysis revealed a dose dependent upregulation of HK2 and Glut 1 proteins at 3, 6 and 24 h with maximal and significant upregulation occurring at 24 h for both proteins [Fig. 2(C) ]. To further investigate whether BCP treated cells were altering their energy metabolism to a more glycolytic state, we measured both glycolysis and oxidative phosphorylation using the Seahorse XF-Analyzer. Macrophages were seeded into a Seahorse microplate and stimulated with BCP crystals for 3, 6 or 24 h. The rates of glycolysis and oxidative phosphorylation were determined by the measurement of ECAR (extracellular acidification rate) and OCR (oxygen consumption rate), respectively, before and after injections of oligomycin, FCCP, rotenone, antimycin A and 2-DG. Overall, the ECAR of BCP-treated cells was higher than untreated controls with the highest ECAR observed at 3 h post-stimulation [ Fig. 2(D) ]. The basal rate of glycolysis was increased in BCP-treated macrophages at all time points, compared to that of untreated control cells [ Fig. 2(G) ], while the maximum rate of glycolysis, was also enhanced in BCP stimulated cells, peaking at 3 h [ Fig. 3(H) ]. The respiratory profiles of macrophages appeared to mirror their observed glycolytic activity with 3 and 6 h BCP stimulation inducing the highest OCR, while 24 h stimulation appeared to marginally reduce OCR [ Fig. 2 (E) ].
This was reflected in the calculated basal respiration and max respiration (Fig. S5) . Importantly, the ECAR:OCR ratio was increased in BCP treated cells at all time points tested [ Fig. 2 (I) ]. We also compared the metabolic profile of BCP-treated cells to that of a known PAMP, LPS which was marginally more potent than BCP at driving CXCL9 and CXCL10 gene expression (Figs. S6(I) and (J)). While both treatments enhanced glycolysis as well as oxidative phosphorylation (Figs. S5(A)e(H) ), overall the ECAR/OCR ratio was higher for BCP-treated macrophages suggesting that it may be a more potent inducer of glycolysis [ Fig. 2(J) ]. Furthermore, when ATP production rate was assessed post BCP treatment, total cellular ATP was significantly enhanced at all time points tested, with BCPtreatment resulting in an increase in glycoATP production rates and a decrease in mitoATP production rates [ Fig. 2(D) ]. Taken together, these data indicate that human macrophages promote glycolytic metabolism upon BCP stimulation.
Macrophage polarization and metabolic reprogramming by BCP crystals is dependent on particle uptake
Having established that BCP crystals can induce a metabolic switch in human macrophages, it was of interest to determine if these responses are dependent on particle uptake. To test this, macrophages were pre-treated with the actin polymerization inhibitor, Latrunculin B (1mM) (to inhibit phagocytosis) for 45 min prior to stimulation with BCP crystals. Results demonstrate that BCP induced CXCL9 and CXCL10 mRNA expression was significantly reduced in the presence of latrunculin B [Fig. 3(A) and (B) ]. Inhibiton of particle uptake also significantly reduced BCP crystal induced IL-8 production [ Fig. 3(C) ] as well as mRNA expression of the glycolytic markers, HK2, Glut1 and HIF1a [ Fig. 3 (D)e(F)]. To ensure that these observations were not due to loss of membrane integrity, which has been associated with Latrunculin B 36 , cells were also pre-treated with the alternative actin polymerization inhibitors Cytochalasin D and B (5mM) and the dynamin inhibitor, Dynasore (80mM) prior to stimulation with BCP crystals. Similar trends were observed with all three inhibitors of phagocytosis (Fig. S7) . Taken together, this indicates that particle uptake is essential for BCP crystal mediated activation of macrophages and glycolytic gene expression.
Inhibition of glycolysis abrogates BCP crystal induced macrophage polarization and alarmin expression
To elucidate if direct inhibition of glycolysis abrogates BCP crystal induced macrophage polarization, cells were stimulated with BCP crystals as described, in the presence or absence of the glycolytic inhibitor, 2-DG. Pre-treatment of cells with 2-DG resulted in a significant decrease of BCP induced CXCL9 and CXCL10 mRNA expression [ Fig. 4(A) and (B) ]. We have previously demonstrated that BCP crystals strongly upregulate expression of the alarmin S100A8 29, 30 which together with S100A9, is heavily implicated in driving catabolic processes in OA 37e39 . mRNA expression of S100A8 was significantly inhibited in the presence of 2-DG [( Fig. 4(C) ] suggesting that inhibition of macrophage metabolic reprogramming impacts on the ability of BCP crystals to induce alarmin expression. Finally, inhibition of glycolysis with 2-DG decreased surface maker expression of CD40, CD80 and CD86 in BCP treated macrophages [ Fig. 4(D) and (E)]. Taken together, the results suggest that glycolytic blockade inhibits BCP-induced pro-inflammatory effects in macrophages.
Discussion
While several studies have demonstrated that impaired mitochondrial dysfunction contributes to pro-catabolic processes in OA chondrocytes, the factors contributing to this phenomenon have not been fully characterized 21 . Furthermore, there have been few studies examining metabolic reprogramming in OA synovial fibroblasts or macrophages. During infection, stimulation of pattern recognition receptors (PRRs) leads to enhanced glycolysis which enables immune cells to generate sufficient ATP and proinflammatory mediators required to carry out effector functions 3 . It is now well accepted that sterile tissue injury can provoke an immune response analogous to that seen during infection and that endogenous molecules generated upon tissue damage are capable of exerting similar effects on cellular processes. Hence, while the switch to a highly active metabolic state is necessary for immune cell activation during infection, metabolic reprogramming by DAMPs/alarmins in the absence of infection has the potential to exacerbate existing inflammation. We now demonstrate that BCP crystals which are OA-associated DAMPs, polarize primary human macrophages towards an M1-like phenotype, enhancing expression of M1-macrophage associated markers and elevating expression of surface maturation markers. Furthermore, BCP crystal stimulation promotes a bioenergetic switch favouring glycolysis and this is accompanied by increased expression of HIF1a, GLUT1 and hexokinase 2, all of which are surrogate markers of glycolysis. Finally, BCP-induced expression of M1 markers and the alarmin, S100A8, was inhibited in the presence of glycolytic inhibitor, 2DG, suggesting that BCP-induced macrophage polarization and inflammation may be dependent on metabolic reprogramming.
Particulates such as calcium oxalate crystals have previously been reported to promote M1 macrophage polarization 40 and, while a number of studies have investigated metabolic reprogramming in human immune cells in response to exogenous pathogen associated molecules (i.e., PAMPs), to our knowledge this is the first report of an endogenous particulate impacting on immune cell metabolism. We demonstrate that human macrophages stimulated with BCP crystals upregulate both glycolysis and oxidative phosphorylation within hours of activation however, the overall glycolytic and ATP production rate is higher. In our hands, LPS stimulation also resulted in enhanced glycolysis and oxidative phosphorylation in human macrophages however, BCP crystals promoted a higher ECAR:OCR ratio than LPS which is considered a potent PAMP. The observed effects of LPS on ECAR and OCR rates differs from reports in murine DC demonstrating that LPS strongly upregulates aerobic glycolysis whilst simultaneously downregulating oxidative phosphorylation via the action of iNOSderived NO 41, 42 . There is, however, controversy regarding the expression/activity of iNOS in human immune cells 43, 44 and our finding is in agreement with a recent study by Malinarich et al. who reported that, while mature human DC are more glycolytic than immature DC, they do not entirely downregulate oxidative phosphorylation, and instead display a more "balanced" switch to glycolysis whereby glycolysis and oxidative phosphorylation are both upregulated 45 .
BCP crystals have previously been reported to upregulate the expression of inflammatory and catabolic mediators in a number of cell types implicated in OA 24,46e48 . Our results show that, in addition to cytokines, chemokines and MMPs, BCP crystals can also upregulate expression of the key glycolytic enzymes, hexokinase 2, GLUT1 and HIF1a, an effect which was attenuated in the presence of phagocytosis inhibitors. Furthermore, when glycolysis was inhibited with the glucose analog, 2-DG, we observed a notable decrease in M1-macrophage marker expression, in addition to S100A8, which is a key OA-associated DAMP. Further analysis will determine if metabolic targeting impacts on downstream targets of S100A8 which include cytokines such as IL-6 and IL-8, as well as MMPs 1, 9 and 13 29, 49 . Interestingly, BCP crystals themselves were potent drivers of IL-8 expression in our hands. This may represent a feed forward mechanism whereby BCP-induced S100A8 drives expression of IL-8, albeit it should be noted that, while S100A8 is known to stimulate the synovial membrane to generate proinflammatory mediators, including IL-8 50 in OA, this chemokine is generally not implicated in Milwaukee Shoulder Syndrome which is also characterized by BCP crystal deposition 25 . Further study is required to fully elucidate the relationship between BCP crystals, IL-8 and the downstream effects of S100A8 production. It will also be necessary to determine whether BCP crystals drive metabolic reprogramming in synoviocytes from OA patient samples and whether glycolytic inhibitors impact on inflammatory/catabolic processes. Indeed, upregulation of glucose transport and an increase in glycolytic metabolism has been demonstrated in OA and particularly in chondrocytes were accumulation of lactic acid contributes to matrix acidification and impaired ECM synthetic function 51e54 . Less is known regarding metabolic disturbances in OA-synoviocytes, however an increase in the glycolysis/OXPHOS ratio has been observed in OA-FLS 21 . Furthermore, silencing of PHD2, a global negative regulator of HIF-1a expression decreased expression of angiogenic genes, while high glucose levels were shown to induce ROS and VEGF in OA-FLS further implicating a metabolic switch and increased glucose transport in synovial joint cells in OA 55, 56 .
While the field of immunometabolism is still in its infancy and much remains to be learned regarding the impact of metabolic reprogramming on disease pathogenesis, ultimately it may be possible to modulate metabolic changes in polarized macrophages by specifically targeting key glycolytic enzymes. However, extreme caution is required given the strong potential for off target effects. This is of particular importance in OA given that chondrocytes, in particular, exist in a hypoxic environment and rely on HIF1a and glycolysis to maintain homeostasis. Currently, there are no drugs available to target BCP crystal deposition in the OA joint and subsequent inflammatory responses, however, based on the above findings, we propose that targeting BCP-and DAMP-induced metabolic reprogramming represents a novel avenue that requires further consideration and exploration.
